Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Final Report of Reduced Anthracycline Dose Intensity with the Addition of Dose Dense Rituximab in Children, Adolescents and Young Adults with De Novo Good Risk Mature B-Cell Non Hodgkin Lymphoma (B-NHL)

Jessica C. Hochberg, MD, Stanton Goldman, MD, Matthew J. Barth, MD, Qiuhu Shi, PhD, Liana Klejmont, Pharm D, Lauren Harrison, RN, MSN, Jackie Basso, Yaya Chu, PhD, Humayun Islam, Perry Gerard, MD MBA, FACR, Javier Oesterheld, MD, Kenneth Matthew Heym, MD, Ivan I. Kirov, MD, Richard A. Drachtman, MD, Paul Harker-Murray, MD PhD, Sherrie L. Perkins, MD PhD, Rodney R. Miles, MD PhD, Bruce Shiramizu, MD, Mitchell S Cairo, MD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-139464

Published: 2020

Journal Articles

BCL-Xl Expression Is Druggable Biomarker Associated with a Poor Clinical Outcome in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Juan J. Gu, MD PhD, Michael Vacaro, Kris Attwood, PhD MS, Cory Mavis, MSc, Pallawi Torka, MD, Matthew J. Barth, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2019) 134 (Supplement_1): 1629.

https://doi.org/10.1182/blood-2019-128512

Published: 2019

Journal Articles

Polatuzumab Vedotin, an Antibody-Drug Conjugate Targeting CD79b, Is a Highly Active Agent Against Burkitt Lymphoma and Primary Mediastinal B-Cell Lymphoma

Anthony N. Audino, MD, Matthew J. Barth, MD, Aradhana Tiwari, PhD, Dina Edani, MS, Janet Ayello, MS, MT(ASCP), Lauren Harrison, RN, MSN, Erin Morris, RN, BSN, Jessica C. Hochberg, MD, Stanton Goldman, MD, Christian Klein, PhD, Mitchell S Cairo, MD

Blood (2019) 134 (Supplement_1): 3963.

https://doi.org/10.1182/blood-2019-128580

Published: 2019

Journal Articles

Targeting MDM2 and XIAP By Idasanutlin in Diffuse Large B-Cell Lymphoma

Juan J. Gu, MD PhD, Samuel J. Thompson, Cory Mavis, MSc, Matthew J. Barth, MD, Pallawi Torka, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2019) 134 (Supplement_1): 5301.

https://doi.org/10.1182/blood-2019-129009

Published: 2019

Journal Articles

MCL-1 Inhibition By the Selective MCL-1 Inhibitor AMG-176 Induces in Vitro Activity Against Burkitt Lymphoma Cell Lines and Synergistically Enhances the Cytotoxic Effect of Chemotherapy and BH3 Mimetics

Tara Daly, BS, Thomas Ippolito, MSc, Juan J. Gu, MD PhD, Cory Mavis, MSc, Pallawi Torka, MD, Francisco J. Hernandez-Ilizaliturri, MD, Matthew J. Barth, MD

Blood (2019) 134 (Supplement_1): 5303.

https://doi.org/10.1182/blood-2019-129052

Published: 2019

Journal Articles

Omipalisib (GSK458), a Dual an-PI3K/mTOR Inhibitor, Exhibits in Vitro and In Vivo activity in Chemotherapy-Sensitive and -Resistant Models of Burkitt Lymphoma

Thomas Ippolito, MSc, Cory Mavis, BSc, MSc, Juan Gu, MD PhD, Francisco J. Hernandez-Ilizaliturri, MD, Matthew J. Barth, MD

Blood (2018) 132 (Supplement 1): 2951.

https://doi.org/10.1182/blood-2018-99-119048

Published: 2018

Journal Articles

High Mir-17-92 Expression Is Associated with in Vitro chemoresistance in Burkitt Lymphoma

Thomas Ippolito, MSc, Rodney R. Miles, MD PhD, Vladimir Rodic, Cory Mavis, MSc, Francisco J. Hernandez-Ilizaliturri, MD, Matthew J. Barth, MD

Blood (2018) 132 (Supplement 1): 1586.

https://doi.org/10.1182/blood-2018-99-118932

Published: 2018

Journal Articles

Targeting XIAP Via Degradation of MDM-2 By MX69 in Aggressive Lymphomas

Sumera Khan, MSc, MD, Kyle Runckel, BS, Cory Mavis, BSc, MSc, Matthew J. Barth, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2018) 132 (Supplement 1): 5379.

https://doi.org/10.1182/blood-2018-99-118480

Published: 2018

Journal Articles

Regulation of Cytokines/Chemokines Release and Anti-Tumor Effect of Expanded Natural Killer (NK) Cells By a Novel Fusion of N-820 (2B8T2M), an IL-15 Superagonist with 4 Single-Chain Anti-CD20 Antibody Domains, Against Rituximab Resistant Burkitt Lymphoma (BL)

Yaya Chu, PhD, Nang Kham Su, MS, Emily K Jeng, Sarah Alter, PhD, Peter R Rhode, PhD, John H Lee, MD, Gaurav Nayyar, MD PhD, Matthew J. Barth, MD, Dean Anthony Lee, MD PhD, Hing C Wong, PhD, Mitchell Cairo, MD

Blood (2018) 132 (Supplement 1): 3697.

https://doi.org/10.1182/blood-2018-99-117683

Published: 2018

Journal Articles

Therapeutic Effects of a Novel Fusion of ALT-803, an IL-15 Superagonist, with 4 Single-Chains of Anti-CD20 Antibody (2B8T2M) in Combination with Expanded Natural Killer Cells Against Rituximab Sensitive and Resistant Burkitt Lymphoma (BL)

Yaya Chu, PhD, Nang Kham Su, BS, Sarah Alter, PhD, Emily K Jeng, Peter R Rhode, PhD, Matthew J. Barth, MD, Dean Anthony Lee, MD PhD, Hing C Wong, PhD, Mitchell S. Cairo, MD

Blood (2017) 130 (Supplement 1): 3587.

https://doi.org/10.1182/blood.V130.Suppl_1.3587.3587

Published: 2017

Journal Articles

Pre-Clinical Development of Targeted Therapies for Double Hit (DH) Diffuse Large B-Cell Lymphoma (DLBCL)

Cory Mavis, BSc, MSc, Pallawi Torka, MD, Alison Zeccola, Priyank P. Patel, MD, Juan Gu, MD PhD, Matthew J. Barth, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2017) 130 (Supplement 1): 1542.

https://doi.org/10.1182/blood.V130.Suppl_1.1542.1542

Published: 2017

Journal Articles

The Adhesion Molecule ICAM-1 in Diffuse Large B-Cell Lymphoma Post-Rituximab Era: Relationship with Prognostic Importance and Rituximab Resistance

Qunling Zhang, MD PhD, Juan J Gu, PhD, Cory Mavis, MSc, Ye Guo, MD, Matthew J. Barth, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2016) 128 (22): 4212.

https://doi.org/10.1182/blood.V128.22.4212.4212

Published: 2016

Journal Articles

Microrna (miR)-17-92 Contributes to Therapy Resistance in Burkitt Lymphoma Cells

Rodney R. Miles, MD PhD, Vladimir Rodic, Matthew J. Barth, MD, Mitchell S. Cairo, MD, Michelle L. Hermiston, MD PhD

Blood (2016) 128 (22): 2944.

https://doi.org/10.1182/blood.V128.22.2944.2944

Published: 2016

Journal Articles

JQ1, a c-MYC Inhibitor Targets Hexokinase II and Enhances the Cytotoxic Effects of Chemotherapeutic Agents in Diffuse Large B-Cell Lymphoma (DLBCL)

Juan J Gu, PhD, Matthew J. Barth, MD, Qunling Zhang, MD PhD, Cory Mavis, MSc, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2016) 128 (22): 5378.

https://doi.org/10.1182/blood.V128.22.5378.5378

Published: 2016

Journal Articles

Itraconazole, an Oral Antifungal Drug, Inhibits Tumor Growth and Enhances Therapeutic Agent Activity in Double Hit Lymphoma

Juan J Gu, PhD, Lianjuan Yang, MD, Benjamin Jarmusz, Daniel Cress, Cory Mavis, MSc, Matthew J. Barth, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2016) 128 (22): 5380.

https://doi.org/10.1182/blood.V128.22.5380.5380

Published: 2016

Journal Articles

Targeting BET Bromodomains in Pre-Clinical Models of Burkitt Lymphoma

Thomas Ippolito, MS, Juan J Gu, PhD, Gregory Tang, Cory Mavis, MSc, Rodney R. Miles, MD PhD, Francisco J. Hernandez-Ilizaliturri, MD, Matthew J. Barth, MD

Blood (2016) 128 (22): 5381.

https://doi.org/10.1182/blood.V128.22.5381.5381

Published: 2016

Journal Articles

Omipalisib (GSK458), a Novel Pan-PI3K/mTOR Inhibitor, Exhibits In Vitro Anti-Lymphoma Activity in Chemotherapy-Sensitive and -Resistant Models of Burkitt Lymphoma

Thomas Ippolito, MS, Greg Tang, Cory Mavis, MSc, Juan J Gu, PhD, Francisco J. Hernandez-Ilizaliturri, MD, Matthew J. Barth, MD

Blood (2016) 128 (22): 5376.

https://doi.org/10.1182/blood.V128.22.5376.5376

Published: 2016

Journal Articles

Itraconazole, an Oral Antifungal Drug, Is Active in Chemotherapy Resistant B-Cell Non-Hodgkin Lymphoma and Enhances the Anti-Tumor Activity of Chemotherapy Agents

Juan J Gu, PhD, Lianjuan Yang, MD, Cory Mavis, MSc, Matthew J. Barth, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2016) 128 (22): 5138.

https://doi.org/10.1182/blood.V128.22.5138.5138

Published: 2016

Journal Articles

PI3K/Akt/mTOR Pathway Inhibition in Chemotherapy-Sensitive and -Resistant Models of Burkitt Lymphoma

Maria Bhatti, MD, Thomas Ippolito, MS, Cory Mavis, BSc, MSc, Matthew J. Barth, MD

Blood (2015) 126 (23): 1558.

https://doi.org/10.1182/blood.V126.23.1558.1558

Published: 2015

Journal Articles

Ibrutinib Significantly Prolonged Survival in a Human Burkitt Lymphoma (BL) Xenograft NSG Mouse Model: Ibrutinib May be a Potential Adjuvant Agent in the Treatment of BL

Sanghoon Lee, PhD MSc., Changhong Yin, MD MS, Janet Ayello, MS, Erin Morris, RN, Timmy O'Connell, MS, Lauren Harrison, RN, MSN, Carmella van de Ven, MA, Matthew J. Barth, MD, Rodney R. Miles, MD PhD, Paul J. Galardy, MD, Stanton Goldman, MD, Megan S Lim, MD PhD, Michelle L. Hermiston, MD PhD, Linda McAllister-Lucas, MDPhD, Lisa Giulino-Roth, MD, Sherrie L. Perkins, MD PhD, Mitchell S. Cairo, MD

Blood (2015) 126 (23): 5117.

https://doi.org/10.1182/blood.V126.23.5117.5117

Published: 2015

NARROW

Final Report of Reduced Anthracycline Dose Intensity with the Addition of Dose Dense Rituximab in Children, Adolescents and Young Adults with De Novo Good Risk Mature B-Cell Non Hodgkin Lymphoma (B-NHL)

BCL-Xl Expression Is Druggable Biomarker Associated with a Poor Clinical Outcome in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Polatuzumab Vedotin, an Antibody-Drug Conjugate Targeting CD79b, Is a Highly Active Agent Against Burkitt Lymphoma and Primary Mediastinal B-Cell Lymphoma

Targeting MDM2 and XIAP By Idasanutlin in Diffuse Large B-Cell Lymphoma

MCL-1 Inhibition By the Selective MCL-1 Inhibitor AMG-176 Induces in Vitro Activity Against Burkitt Lymphoma Cell Lines and Synergistically Enhances the Cytotoxic Effect of Chemotherapy and BH3 Mimetics

Omipalisib (GSK458), a Dual an-PI3K/mTOR Inhibitor, Exhibits in Vitro and In Vivo activity in Chemotherapy-Sensitive and -Resistant Models of Burkitt Lymphoma

High Mir-17-92 Expression Is Associated with in Vitro chemoresistance in Burkitt Lymphoma

Targeting XIAP Via Degradation of MDM-2 By MX69 in Aggressive Lymphomas

Regulation of Cytokines/Chemokines Release and Anti-Tumor Effect of Expanded Natural Killer (NK) Cells By a Novel Fusion of N-820 (2B8T2M), an IL-15 Superagonist with 4 Single-Chain Anti-CD20 Antibody Domains, Against Rituximab Resistant Burkitt Lymphoma (BL)

Therapeutic Effects of a Novel Fusion of ALT-803, an IL-15 Superagonist, with 4 Single-Chains of Anti-CD20 Antibody (2B8T2M) in Combination with Expanded Natural Killer Cells Against Rituximab Sensitive and Resistant Burkitt Lymphoma (BL)

Pre-Clinical Development of Targeted Therapies for Double Hit (DH) Diffuse Large B-Cell Lymphoma (DLBCL)

The Adhesion Molecule ICAM-1 in Diffuse Large B-Cell Lymphoma Post-Rituximab Era: Relationship with Prognostic Importance and Rituximab Resistance

Microrna (miR)-17-92 Contributes to Therapy Resistance in Burkitt Lymphoma Cells

JQ1, a c-MYC Inhibitor Targets Hexokinase II and Enhances the Cytotoxic Effects of Chemotherapeutic Agents in Diffuse Large B-Cell Lymphoma (DLBCL)

Itraconazole, an Oral Antifungal Drug, Inhibits Tumor Growth and Enhances Therapeutic Agent Activity in Double Hit Lymphoma

Targeting BET Bromodomains in Pre-Clinical Models of Burkitt Lymphoma

Omipalisib (GSK458), a Novel Pan-PI3K/mTOR Inhibitor, Exhibits In Vitro Anti-Lymphoma Activity in Chemotherapy-Sensitive and -Resistant Models of Burkitt Lymphoma

Itraconazole, an Oral Antifungal Drug, Is Active in Chemotherapy Resistant B-Cell Non-Hodgkin Lymphoma and Enhances the Anti-Tumor Activity of Chemotherapy Agents

PI3K/Akt/mTOR Pathway Inhibition in Chemotherapy-Sensitive and -Resistant Models of Burkitt Lymphoma

Ibrutinib Significantly Prolonged Survival in a Human Burkitt Lymphoma (BL) Xenograft NSG Mouse Model: Ibrutinib May be a Potential Adjuvant Agent in the Treatment of BL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only